Regeneron – good or bad?
25 November 2020, 6:00 pm–7:30 pm
The annual UCL Institute of Brand & Innovation Law (IBIL) innovation seminar
UCL Laws Events
About this event
Earlier this year in June, the UK Supreme Court handed down the long-awaited judgment in Regeneron Pharmaceuticals Inc v Kymab Ltd  UKSC 27. The Court, by a majority of four to one, found Regeneron's antibody patents invalid for insufficiency, thus overturning the Court of Appeal’s decision. In the Court’s view, a patent claim lacks sufficient support if it is not enabled across its entire scope - since the patent bargain requires the monopoly granted to match the contribution made to the art.
But was the Supreme Court right? Can a principle of general application now be patented? And if so, how?
- Professor Dr. Klaus Bacher, Presiding Judge, 10th Senate of the German Supreme Court
- Nicola Dagg, Partner at Kirkland & Ellis International LLP, London – solicitors for Regeneron Pharmaceuticals Inc
- Dr Penny Gilbert, Partner at Powell Gilbert LLP, London – solicitors for Kymab Ltd
- The Rt Hon. Lord Leonard Hoffmann, Honorary Professor of Intellectual Property Law, QMUL; Visiting Professor, Faculty of Law, Oxford University; Chair of the Institute of Intellectual Property Research Council; Judge of the Court of Final Appeal of Hong Kong.
- Judge Kathleen O'Malley, U.S. Court of Appeals for the Federal Circuit.
- Dr Matt Fisher, UCL Faculty of Laws, Co-director of the UCL Institute of Brand and Innovation Law